SPRB logo

Spruce Biosciences (SPRB)

Profile

Full Name

Spruce Biosciences, Inc.

Ticker Symbol

SPRB

Exchange

NASDAQ

Country

United States

IPO

October 9, 2020

Indexes

Not included

Employees

22

Key Details

Price

$0.12(-4.07%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$10.09M

Annual EPS

-$1.24(+36.73% YoY)

PE ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Dec 16, 24 HC Wainwright & Co.
Neutral
Dec 12, 24 Guggenheim
Neutral
Dec 11, 24 RBC Capital
Sector Perform
Dec 11, 24 Oppenheimer
Perform
Dec 11, 24 JMP Securities
Market Perform
Nov 12, 24 RBC Capital
Sector Perform
Aug 19, 24 HC Wainwright & Co.
Neutral
Aug 13, 24 RBC Capital
Sector Perform
Jun 13, 24 Oppenheimer
Outperform
Jun 5, 24 HC Wainwright & Co.
Neutral

Institutional Ownership

  • What is the ticker symbol for Spruce Biosciences?
  • Does Spruce Biosciences pay dividends?
  • What sector is Spruce Biosciences in?
  • What industry is Spruce Biosciences in?
  • What country is Spruce Biosciences based in?
  • When did Spruce Biosciences go public?
  • Is Spruce Biosciences in the S&P 500?
  • Is Spruce Biosciences in the NASDAQ 100?
  • Is Spruce Biosciences in the Dow Jones?
  • When was Spruce Biosciences's last earnings report?
  • When does Spruce Biosciences report earnings?
  • Should I buy Spruce Biosciences stock now?

What is the ticker symbol for Spruce Biosciences?

The ticker symbol for Spruce Biosciences is NASDAQ:SPRB

Does Spruce Biosciences pay dividends?

No, Spruce Biosciences does not pay dividends

What sector is Spruce Biosciences in?

Spruce Biosciences is in the Healthcare sector

What industry is Spruce Biosciences in?

Spruce Biosciences is in the Biotechnology industry

What country is Spruce Biosciences based in?

Spruce Biosciences is headquartered in United States

When did Spruce Biosciences go public?

Spruce Biosciences's initial public offering (IPO) was on October 9, 2020

Is Spruce Biosciences in the S&P 500?

No, Spruce Biosciences is not included in the S&P 500 index

Is Spruce Biosciences in the NASDAQ 100?

No, Spruce Biosciences is not included in the NASDAQ 100 index

Is Spruce Biosciences in the Dow Jones?

No, Spruce Biosciences is not included in the Dow Jones index

When was Spruce Biosciences's last earnings report?

Spruce Biosciences's most recent earnings report was on Nov 11, 2024

When does Spruce Biosciences report earnings?

The next expected earnings date for Spruce Biosciences is May 13, 2025

Should I buy Spruce Biosciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page